| I. Guidelines for the management of LRTIs |
| 1. Does your country have national/sub-national guidelines for the management of LRTIs? |
| 2. Do the guidelines for the management of LRTIs consider the ERS guidelines for the management of adult respiratory tract infections? |
| 3. Do the guidelines for the management of LRTIs include recommendations on the differential diagnosis, treatment and management of TB? |
| a. If no, do the national guidelines for the management of LRTIs include information on how and where to refer suspected TB patients for diagnosis, treatment and management? |
| 4. Do the guidelines for the management of LRTIs include recommendations on the use of FQ in LRTIs and the risk for development of FQ-resistant TB in misdiagnosed patients? |
| 5. Do the guidelines for the management of LRTI recommend FQ as:</p> |
| a. First drug of choice to treat LRTI? |
| b. Second drug of choice to treat LRTI? |
| II. Guidelines for the management of CAP |
| 1. Does your country have national/sub-national guidelines specifically for the management of CAP? |
| 2. Do the guidelines for the management of CAP consider the ERS guidelines for the management of adult respiratory tract infections? |
| 3. Do the guidelines for the management of CAP include recommendations on the differential diagnosis and treatment of TB? |
| 4. If no, do the national guidelines for the management of CAP include information on how and where to refer suspected TB patients for diagnosis, treatment and management? |
| 5. Do the guidelines for the management of CAP include recommendations on the use of FQ in CAP and the risk of development of FQ-resistant TB in misdiagnosed patients? |
| 6. Do the guidelines for the management of CAP recommend FQ as: |
| a. First drug of choice to treat CAP? |
| b. Second drug of choice to treat CAP? |
TB: tuberculosis; FQ: fluoroquinolones.